Related Experiment Video
Updated: Jul 6, 2025

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
Published on: February 23, 2024
Integration of Computational Docking into Anti-Cancer Drug Response Prediction Models
Oleksandr Narykov1, Yitan Zhu1, Thomas Brettin1
1Computing, Environment and Life Sciences, Argonne National Laboratory, Lemont, IL 60439, USA.
Abstract:
Cancer is a heterogeneous disease in that tumors of the same histology type can respond differently to a treatment. Anti-cancer drug response prediction is of paramount importance for both drug development and patient treatment design. Although various computational methods and data have been used to develop drug response prediction models, it remains a challenging problem due to the complexities of cancer mechanisms and cancer-drug interactions. To better characterize the interaction between cancer and drugs, we investigate the feasibility of integrating computationally derived features of molecular mechanisms of action into prediction models. Specifically, we add docking scores of drug molecules and target proteins in combination with cancer gene expressions and molecular drug descriptors for building response models. The results demonstrate a marginal improvement in drug response prediction performance when adding docking scores as additional features, through tests on large drug screening data. We discuss the limitations of the current approach and provide the research community with a baseline dataset of the large-scale computational docking for anti-cancer drugs.
Insights
Integrating molecular docking scores into computational models offers a marginal improvement for predicting anti-cancer drug response. This study provides a baseline dataset for computational docking of anti-cancer drugs.
Area of Science:
- Oncology
- Computational Biology
- Pharmacology
Background:
- Cancer exhibits heterogeneity, leading to varied responses to treatments even among tumors of the same histology.
- Accurate anti-cancer drug response prediction is crucial for effective drug development and personalized patient treatment strategies.
- Current computational models face challenges due to the complex mechanisms of cancer and drug interactions.
Purpose of the Study:
- To investigate the integration of computationally derived molecular mechanism of action features into anti-cancer drug response prediction models.
- To assess the feasibility of enhancing prediction accuracy by incorporating molecular docking scores alongside gene expression and drug descriptors.
Main Methods:
- Utilized cancer gene expression data and molecular drug descriptors.
- Integrated computationally derived docking scores between drug molecules and target proteins.
- Developed and tested response prediction models using these combined features on large-scale drug screening data.
Main Results:
- A marginal improvement in anti-cancer drug response prediction performance was observed when docking scores were included as additional features.
- The study established a baseline dataset of large-scale computational docking for anti-cancer drugs.
Conclusions:
- Integrating molecular docking information shows potential for enhancing computational drug response prediction models.
- Further research is needed to overcome limitations and refine the approach for more significant predictive power.
More Related Videos
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
Related Concept Videos
Ligand Binding Sites
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Protein-protein Interfaces
Treatment Resistant Cancers